BUSINESS
    Roche Proposes Ex-Takeda CEO Weber for Board
    September 24, 2026
    Roche said on September 23 that it will nominate former Takeda Pharmaceutical President and CEO Christophe Weber to its board of directors, with his appointment slated for March 2027.Weber will be put forward for election…

    LATEST

    Astellas Starts Setidegrasib PIII in KRAS G12D-Mutated NSCLC
    September 24, 2026
    Astellas Pharma said on September 24 that the first patient has been dosed in a global PIII trial of its targeted protein degrader setidegrasib in KRAS G12D-mutated non-small cell lung cancer (NSCLC) — the second…
    Otsuka’s Antisense Drug Hits PIII Goal in FUS-ALS
    September 24, 2026
    Otsuka Pharmaceutical said on September 22 that ulefnersen, an antisense oligonucleotide it licensed from US biotech Ionis Pharmaceuticals, met the primary endpoint in a global PIII trial for FUS-ALS, a form of ALS caused by…
    EU Panel Backs Enhertu for Adjuvant Use in HER2-Positive Breast Cancer
    September 24, 2026
    Daiichi Sankyo said on September 18 that an EU regulatory panel has recommended approval of its anti-HER2 antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) as an adjuvant monotherapy for certain patients with HER2-positive breast cancer.The…

    Chuikyo Debate on FY2026 Drug Pricing Reform

    Romiplate to See Steepest Cut in April Market Expansion Re-Pricing

    Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

    COMMENTARY

    Regional Formularies Gain Ground, Raising Stakes for Drug Makers, Wholesalers
    By Tatsuya Otsuka

    Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…

    COLUMN

    The One Mistake on Your Resume
    By Philip Carrigan

    We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…

    Drug Approval & Reimbursement in 2025

    Chuikyo OKs Listing of Novartis’ Pluvicto, Peak Sales Outlook at 42.1 Billion Yen

    Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

    Chuikyo Debate on Off-Year Drug Price Revisions

    MHLW Unveils New List Prices for FY2025 Revision; Stelara, Januvia Hit by PMP Return
    By Ken Yoshino

    The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

    Discussions on Next PMD Act Amendment

    Japan Cabinet Approves Bill to Amend PMD Act

    The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

    Drug Approval & Reimbursement in 2024

    Japan Approves Zepbound, Qalsody, and Lots More Drugs

    Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

    Chuikyo on FY2024 Reimbursement Reform

    Chuikyo OKs Outline of FY2024 Drug Pricing Reform; No Unprofitability Re-Pricing for 7%-Plus Price Gap

    Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

    NEWS CATEGORY

    REGULATORY

    BUSINESS

    ORGANIZATION

    ACADEMIA